Positron Corporation (POSC)

[JackStraw]

POSITRON JOINS MEDAXIOM AS A CORPORATE PARTNER

INDIANAPOLIS—July 16, 2009 (BUSINESS WIRE)--Positron Corporation (OTCBB:POSC.OB - News) (the “Company”), a molecular imaging solutions company focused on Nuclear Cardiology, announced today that they have signed on as a Corporate Partner with MedAxiom. MedAxiom is a comprehensive subscription-based service provider and information resource exclusively for cardiology practices. MedAxiom’s network is compiled of over 300 practices representing 5,400 physicians covering 45 states across the U.S. MedAxiom is a community of cardiology practice executives, administrative leaders, physicians and business office teams that strive to be more effective and efficient through sharing of operational practice data, best practice business strategies, positive and negative experiences as well as insights into the future of cardiology.
“Aligning with MedAxiom provides Positron direct access to most all cardiology practices in the country and many that are in the immediate market for Positron’s products,” stated Mark Wilson, Director of Business Development for Positron Corporation. “The MedAxiom membership is our exact target market. The products and services which Positron provides truly benefit the types of cardiology groups that make up the MedAxiom membership and community. Positron’s solutions for PET and SPECT address the evolving market conditions that face all cardiology groups today.”
“The new Corporate Partnership between MedAxiom and Positron is a timely one and we’re very excited to help bring the Positron technology to our member practices. Because of the Mo99 shortage, more MedAxiom members are being forced to look at alternative clinical options such as PET” said Chris Romeo, Vice President of Corporate Relations. “The recent 510(k) approval of the Positron PET scanner, the Attrius™, now allows for this proven technology (PET) to be delivered to the cardiology practice environment in a much more affordable means.”